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1. General Information 
 
Unless otherwise stated, all reactions were performed under argon atmosphere using flame-dried 
glassware. Commercially available compounds were used without further purification. DMF was 
distilled from CaH2. NMR experiments were performed in deuterated solvents. 
1H NMR, 13C 
NMR, 11B NMR and 19F spectra were recorded on 400 and 500 MHz spectrometers. Chemical 
shifts are reported in parts per million (ppm) relative to the residual protium in the solvents (1H) 
or the solvent carbon (13C) as internal standards. 1H NMR spectral data features are tabulated in 
the following order: chemical shift in ppm (δ) (multiplicity, coupling constant, integration, type 
of H). The following abbreviations were used in reporting NMR data: s, singlet; br s, broad 
singlet; d, doublet; t, triplet; q, quartet; dd, doublet of doublets; dt, doublet of triplet; td, triplet of 
doublet; ddd, doublet of doublet of doublet; m, multiplet; sept, septet; quin, quintet. Because of 
their low intensity (resulting from quadruple coupling), 13C signals arising from the quaternary 
carbon bearing the borinic acid group were not always observed and therefore were not always 
listed. Chromatographic separations were achieved on silica gel columns (Kieselgel 60, 40-63 
µm). Detection was accomplished by irradiation with a UV lamp or staining with KMnO4. IR 
Spectra were recorded on a FTIR spectrometer with frequencies expressed in cm-1. HSQCETGP 
(2D H-1/X correlation via double inept transfer phase sensitive using Echo/Antiecho-TPPI 
gradient selection with decoupling during acquisition using trim pulses in inept transfer). 
HMBCGPLPNDQF (2D H-1/X correlation via heteronuclear zero and double quantum coherence 
optimized on long range couplings with low-pass J-filter to suppress one-bond correlations no 
decoupling during acquisition using gradient pulses for selection). DEPT135 (dept polarization 
transfer with 135 degree read pulse to give XH, XH3 positive and XH2 negative with decoupling 
during acquisition) were used to assign the NMR peaks. Mass Spectra and high-resolution mass 
spectra (HRMS) were obtained on a Q-Tof instrument were recorded using either electron impact 
(EI) or electrospray ionization (ESI) techniques. Powdered molecular sieves were dried for 3 





2. Optimization Experiments 
 
Table 1. Optimization of 1 loading and ratio AcOH:1[a] 
 
 
Entry  AcOH (mol %) 1 (mol %) Isolated Yield (%) 




3 5 93 
4 10 10 80 
 
[a] Reaction conditions: Borinic acid 1 (5-10 mol %) and AcOH (10-40 mol %) in DMF (7 mL) were stirred at 65 °C 
for 15 min before the addition of benzylamine 2a (55.5 μL, 0.50 mmol) and stirring was maintained for further 24 h. 
 As shown by Table 1, a catalyst loading of 10 mol % along with 40 mol % of AcOH provided 
the corresponding benzyl formamide 3a in an excellent yield of 98% (Entry 1). Decreasing the 
amount of AcOH 20 mol % had no impact on the yield (Entry 2). Whereas, upon decreasing the 
catalyst loading to 5 mol % with 20 mol % AcOH, a slight decrease in the yield of 3a was 
observed (93%, Entry 3). A further decrease for AcOH to 10 mol % greatly lowered the yield 
(80%, Entry 4). As a result, the optimal conditions appeared to involve a ratio of 2 : 1 








Table 2. Solvent screening using 1[a] 
 
 
Entry Solvent Yield (%) 
1 THF 15 
2 CH2Cl2 8 
3 MeCN 7 
4 Toluene 5 
5 AcOH 0 
6 DMF 73 
 
[a] Reaction conditions: Borinic acid 1 (10 mol %), AcOH (20 mol %) and DMF (10 eq.) in the chosen solvent (6.6 
mL) were stirred at room temperature for 15 min before the addition of benzylamine 2a (55.5 μL, 0.50 mmol) and 
stirring was maintained for further 24 h. 
The results described in Table 2 showed that using DMF only as a reactant in the presence of 
another co-solvent significantly hindered the N-formylation of benzylamine 2a (Entries1-4). 
However, using AcOH as a solvent completely inhibited the reaction (Entry 5). As a result, DMF 




Optimization of N-formylation of glycine amino ester using HCONH2 
Table 3. Optimisation of temperature using 1[a] 
 
Entry T (°C) Isolated Yield (%) 
1 65 99 
2 45 99 
3 20 80 
[a] Reaction conditions: Borinic acid 1 (10 mol %) and AcOH (20 mol %) in HCONH2 (20 eq.) were stirred at the 
specified temperature for 15 min before the addition of glycine methyl ester amine 7a (40.0 μL, 0.50 mmol) and 
stirring was maintained for further 24 h. 
Taking into account the previous optimal conditions used for the transamidation using DMF 
(Entry 1), we were able to reduce the temperature to 45 °C without affecting the yield of 8a 
(Entry 2). Running the reaction at room temperature provided a lower yield of 80% (Entry 3). 
 
Table 4. Optimisation of catalyst loading of 1[a] 
 
Entry  1 (mol %) Isolated Yield (%) 
1 10 99 
2 5 99 




[a] Reaction conditions: Borinic acid 1 (2.5-10 mol %) and AcOH (20 mol %) in HCONH2 (20 eq.) were stirred at 45 
°C for 15 min before the addition of glycine methyl ester amine 7a (40.0 μL, 0.50 mmol) and stirring was 
maintained for further 24 h. 
As shown by Table 4, a catalyst loading of 10 mol % provided 8a in an excellent yield (Entry 1). 
Decreasing the loading of 1 to 5 mol % and even 2.5 mol % had no effect on the yield which 
remained quantitative (Entries 2 and 3). Thus, 2.5 mol% was chosen as the optimal catalyst 
loading for the N-formylation of α-amino esters using HCONH2. 
 
Table 5. Optimisation of 1:AcOH ratio[a] 
 
Entry AcOH (mol %) Ratio 1 : AcOH Isolated Yield (%) 
1 20 8 : 1 99 
2 10 4 : 1 99 
3 5 2 : 1 60 
 
[a] Reaction conditions: Borinic acid 1 (2.5 mol %) and AcOH (5-20 mol %) in HCONH2 (20 eq.) were stirred at 45 
°C for 15 min before the addition of glycine methyl ester amine 7a (40.0 μL, 0.50 mmol) and stirring was 
maintained for further 24 h. 
As shown by Table 5, using 10 mol % or 20 mol % of AcOH provided 8a in quantitative yield 
(Entries 1 and 2). Decreasing the loading of AcOH down to 05 mol % greatly lowered the yield 
of the reaction to 60% (Entry 3). Thus, the optimal ratio between AcOH and borinic acid was 






Table 6. Optimisation of HCONH2 equivalents using 1
[a] 
 
Entry # eq of HCONH2 Isolated Yield (%) 
1 20 99 
2 10 99 
3 5 99 
 
[a] Reaction conditions: Borinic acid 1 (2.5 mol %) and AcOH (10 mol %) in HCONH2 (x eq.) were stirred at 45 °C 
for 15 min before the addition of glycine methyl ester amine 7a (40.0 μL, 0.50 mmol) and stirring was maintained 
for further 24 h. 
As shown by Table 6, the number of HCONH2 equivalents can be decreased down to 5 eq. while 













3. Mechanistic Studies 
Scheme 1. Monitoring the progress of the reaction using 4 as a 19F probe 
 
All the reactions were carried out at 65 °C in DMF (1 mL) the presence of 1,3,5-trimethoxybenzene as an internal 
standard (20 mol %). (a) 4 (10 mol %). (b) 4 (10 mol %) with AcOH (20 mol %). (c) 4 (10 mol %) with AcOH (20 
mol %) and benzylamine 2a (50 mol %) after 30 min. (d) 4 (10 mol %) with AcOH (20 mol %) and benzylamine 2a 






Scheme 2. Studying the stability of 4 compared to boronic acid analogue 6 
 
All the reactions were carried out at 65 °C in DMF (1 mL) the presence of 1,3,5-trimethoxybenzene as an internal 
standard (20 mol %). (a) 6 (10 mol %). (b) 6 (10 mol %) with AcOH (20 mol %). (c) 6 (10 mol %) with AcOH (20 
mol %) and benzylamine 2a (50 mol %) after 24 h. (d) 4 (10 mol %) with AcOH (20 mol %) and benzylamine 2a (50 
mol %) after 24 h. 
 
 
Scheme 3. Monitoring the progress of the reaction using 11B NMR of the borinic acid catalyst 1 
 
 
All the reactions were carried out in deuterated DMF-d7 at RT. (a) 1 alone. (b) 1 with AcOH (20-40 mol %). (c) 1 




Scheme 4. Monitoring the progress of the reaction using mass spectroscopy 
 
An equimolar mixture of 1 : II observed using LRMS (ESI-TOF) m/z: [M - H]-    
 
4. General Procedure A: N-Formylation of Amines using DMF 
 
To a round-bottom flask under an argon atmosphere were added 2-chlorophenylborinic acid 1 
(12.5 mg, 0.05 mmol, 0.1 equiv.), dry DMF (5 equiv. unless otherwise mentioned) and acetic acid 
(6 mg, 0.10 mmol, 6 µL, 0.2 equiv.). The mixture was vigorously stirred for 15 min at the given 
temperature (Table 2 main article) and the amine (0.50 mmol, 1 equiv.) was then slowly added 
using a gastight syringe. The resulting mixture was stirred for the given time. DMF was removed 
using Kugelrohr distillation apparatus (55 °C) and the residue was purified by column 
chromatography to give the title compounds. A sealed-pressure tube was used for the reactions 





Benzylformamide (3a). Known and described.1 The title compound was prepared according to 
the general procedure A at room temperature for 72 h using benzylamine (55.5 µL, 0.50 mmol). 
It was purified by column chromatography using CH2Cl2/EtOAc (70/30) as the eluent and 
isolated in the form of a colourless solid (58.2 mg, 0.43 mmol, 86%).  Using a temperature of 65 
°C provided a higher yield of 3a within 12 h (67 mg, 0.50 mmol, 99%).  
 
M.p: 62 – 64 °C (lit: 63-64).2 Rf (CH2Cl2/EtOAc: 70/30) = 0.37. The product was obtained in the 
form of 2 rotamers with a ratio of 9:1. The 1H and 13C data were consistent with those reported in 
the literature. 1H NMR (400.0 MHz; CDCl3-d
1) δH = 8.15 (br s, 0.9HCHO), 8.07 (d, J = 12.0 Hz, 
0.1HCHO), 7.37 – 7.22 (m, 5HAr), 6.68 (br s, 0.9 HNH), 6.39 (br s, 0.1HNH), 4.41 (d, J = 6.0 Hz, 
1.8HCH2), 4.34 (d, J = 6.5 Hz, 0.2HCH2). 
13C NMR (101.6 MHz; CDCl3-d
1) δC = 164.7 (C=O minor), 
161.1 (C=O major) 137.6 (CqAr), 129.0 (CHAr minor), 128.8 (CHAr major), 128.0 (CHAr minor) 127.8 
(CHAr major), 127.7 (CHAr major), 127.0 (CHAr minor), 45.7 (CH2 minor) 42.2 (CH2 major).  
 
N-(Pyridine-2-yl)methylformamide (3b). The title compound was prepared according to the 
general procedure A at room temperature for 72 h using 2-picolylamine (52 µL, 0.50 mmol). It 
was purified by column chromatography using CH2Cl2/EtOAc (60/40 to 50/50) as the eluent and 
isolated in the form of a yellow oil (52.4 mg, 0.385 mmol, 77%).  Using a temperature of 65 °C 
provided a higher yield of 3b within 12 h (67.3 mg, 0.49 mmol, 99%). 
 
                                                          
 
1 R. Fu, Y. Yang, Z. Chen, W. Lai, Y. Ma, R. Yuan, Q. Wang, Tetrahedron 2014, 70, 9492–9499. 




Rf (CH2Cl2/EtOAc: 60/40) = 0.10. The product was obtained in the form of 2 rotamers with a 
ratio of 9:1. 1H NMR (400.0 MHz; CDCl3-d
1) δH = 8.54 (d, J = 4.8 Hz, 0.1HNH), 8.50 (d, J = 4.3 
Hz, 0.9HNH), 8.29 (br s, 1HCHO), 7.65 (td, J = 7.6, 1.5 Hz, 1HAr), 7.27-7.25 (m, 2HAr), 7.20-7.17 
(m, 1HAr), 4.58 (d, J = 5.3 Hz, 1.8HCH2), 4.51 (d, J = 6.3 Hz, 0.2HCH2). 
13C NMR (101.6 MHz; 
CDCl3-d
1) δC = 161.2 (C=O), 155.8 (CqAr), 148.8 (CHAr), 136.9 (CHAr), 122.4 (CHAr), 122.0 
(CHAr), 42.9 (CH2 major), 29.6 (CH2 minor). ʋmax (neat)/cm
-1 3284, 3012, 2929, 2863, 1663, 1593, 
1572, 1531, 1477, 1437, 1385, 1242, 1216. HRMS (ESI+ TOF) m/z: [M + H]+ Calcd for 
C7H9N2O
+ : 137.0715; Found: 137.0714.  
 
N-(2-(1H-Indol-3-yl)ethyl)formamide (3c). The title compound was prepared according to the 
general procedure A at room temperature for 72 h using 2–(1H-indol-3-yl)ethanamine (94.1 mg, 
0.50 mmol). It was purified by column chromatography using CH2Cl2/EtOAc (70/30) as the 
eluent and isolated in the form of a brown oil (81.0 mg, 0.43 mmol, 86%). Using a temperature of 
65 °C provided the same yield of 3c within 24 h (94.1 mg, 0.50 mmol, 99%). 
 
Rf (CH2Cl2/EtOAc: 70/43) = 0.22. The product was obtained in the form of 2 rotamers with a 
ratio of 8:2. 1H NMR (400.0 MHz; CDCl3-d
1) δH = 8.65 (br s, 1HNHAr), 7.90 (br s, 0.8HCHO), 7.69 
(br d, J = 12.0 Hz, 0.2HCHO), 7.51 (d, J = 7.8 Hz, 0.8HAr), 7.50-7.47 (m, 0.2HAr), 7.27 (d, J = 7.8 
Hz, 1HAr), 7.13 (t, J = 7.2 Hz, 1HAr), 7.06-7.02 (m, 1HAr), 6.87 (s, 0.8HAr), 6.83 (s, 0.2HAr), 5.92 
(br s, 1HNH), 3.51 (q, J = 6.1 Hz, 1.5HCH2-NH), 3.34 (q, J = 6.0 Hz, 0.5HCH2-NH), 2.87 (t, J = 6.6 
Hz, 1.5HCH2-CH2-NH), 2.81 (t, J = 6.8 Hz, 0.5HCH2-CH2-NH). 
13C NMR (101.6 MHz; CDCl3-d
1) δC = 
164.7 (C=O minor), 161.5 (C=O major), 136.4 (CqAr minor), 136.3 (CqAr major), 127.1 (CqAr major), 126.7 
(CqAr minor), 122.8 (CHAr minor), 122.3 (CHAr major), 122.0 (CHAr minor), 121.9 (CHAr major), 119.3 
(CHAr minor), 119.2 (CHAr major), 118.4 (CHAr major), 118.2 (CHAr minor), 112.0 (CqAr major), 111.5 
(CHAr minor), 111.3 (CHAr major), 111.1 (s, CqAr minor), 42.0 (CH2 minor), 38.3 (CH2 major), 27.1 (CH2 
minor), 24.9 (CH2 major). ʋmax (neat)/cm




1385, 1339, 1216. HRMS (ESI+ TOF) m/z: [M + Na]+ Calcd for C11H12ON2Na
+ : 211.0847; 
Found: 211.0849. 
 
N-(2-Hydroxyethyl)formamide (3d). The title compound was prepared according to the general 
procedure A at room temperature for 72 h using 2-amino-ethan-1-ol (30 µL, 0.50 mmol). It was 
purified by column chromatography using CH2Cl2/MeOH (90/10 to 80/20) as the eluent and 
isolated in the form of a yellow oil (43.8 mg, 0.49 mmol, 98%).  
 
Rf (CH2Cl2/MeOH: 80/20) = 0.18. The product was obtained in the form of 2 rotamers with a 
ratio of 9:1. 1H NMR (400.0 MHz; MeOD-d4) δH = 8.09 (br s, 0.9HCHO), 8.01 (br s, 0.1HCHO), 
3.62 (t, J = 5.7 Hz, 1.6HCH2-OH), 3.59-3.58 (m, 0.4HCH2-OH), 3.35 (t, J = 5.6 Hz, 1.6HCH2-NH), 3.30 
(t, J = 5.5 Hz, 0.4HCH2-NH). 
13C NMR (101.6 MHz; MeOD-d4) δC = 167.9 (C=O minor), 164.2 
(C=O major), 62.5 (CH2 minor), 61.5 (CH2 major), 45.4 (CH2 minor), 41.6 (CH2 major). ʋmax (neat)/cm
-1 
3313, 2940, 2879, 2468, 2387, 1737, 1643, 1536, 1427, 1380, 1228, 1064. HRMS (ESI+ TOF) 
m/z:  [M + Na]+ Calcd for C3H7NO2Na
+ :  112.0374; Found: 112.0380. 
 
N-(3-(Methylthio)propyl)formamide (3e). The title compound was prepared according to the 
general procedure A at room temperature for 72 h using 3-methylthiopropanamine (56 µL, 0.50 
mmol). It was purified by column chromatography using CH2Cl2/EtOAc (80/20 to 70/30) as the 
eluent and isolated in the form of an orange oil (66.3 mg, 0.50 mmol, 99%).  
 
Rf (CH2Cl2/EtOAc: 70/30) = 0.15. The product was obtained in the form of 2 rotamers with a 
ratio of 9:1. 1H NMR (400.0 MHz; CDCl3-d
1) δH = 8.07 (br s, 0.9HCHO), 7.97 (d, J = 12.0 Hz, 




0.2HCH2-NH), 2.46 (t, J = 7.0 Hz, 2HCH2-SMe), 2.02 (s, 3HCH3), 1.79-1.72 (m, 2HCH2-CH2-CH2-NH). 
13C 
NMR (101.6 MHz; CDCl3-d
1) δC = 164.8 (C=O minor), 161.5 (C=O major), 40.1 (CH2 minor), 36.9 
(CH2 major), 31.2 (CH2 major), 30.5 (CH2 minor), 29.5 (CH2 minor), 28.3 (CH2 major), 15.2 (CH3 major), 
15.1 (CH3 minor). ʋmax (neat)/cm
-1 3283, 3055, 2918, 2860, 1658, 1533, 1437, 1384, 1265, 1238, 
1174, 1073. HRMS (ESI+ TOF) m/z: [M + Na]+ Calcd for C5H11NONaS
+ : 156.0459; Found: 
156.0458. 
 
N-(1-Phenylethyl)formamide (3f). Known and described.3 The title compound was prepared 
according to the general procedure A at a temperature of 65 °C for 12 h using 1-phenylethan-1-
amine (65 µL, 0.50 mmol). It was purified by column chromatography using Pentane/EtOAc 
(90/10 to 60/40) as the eluent and isolated in the form of a yellow oil (73.9 mg, 0.50 mmol, 99%). 
 
Rf (CH2Cl2/EtOAc: 80/20) = 0.68. The product was obtained in the form of 2 rotamers with a 
ratio of 8:2. The 1H and 13C data were consistent with those reported in the literature. 1H NMR 
(400.0 MHz; CDCl3-d
1) δH = 8.10 (br s, 0.8HCHO), 8.08 (br s, 0.2HCHO), 7.31-7.26 (m, 3HAr), 
7.25-7.20 (m, 2HAr), 6.00 (br s, 0.2HNH), 5.86 (br s, 0.8HNH), 5.15 (quin, J = 7.3 Hz, 0.8HCH), 
4.63 (quin, J = 7.2 Hz, 0.2HCH), 1.50 (d, J = 7.0 Hz, 0.6HCH3), 1.46 (d, J = 6.9 Hz, 2.4HCH3). 
13C 
NMR (101.6 MHz; CDCl3-d
1) δC = 164.1 (C=O minor), 160.2 (C=O major), 142.7 (CqAr minor), 142.5 
(CqAr major), 128.9 (CHAr minor), 128.7 (CHAr major), 127.7 (CHAr minor), 127.5 (CHAr major), 126.1 
(CHAr major), 125.7 (CHAr minor), 51.6 (CH minor), 47.6 (CH major), 23.6 (CH3 minor), 21.7 (CH3 major).  
N-Cyclopropylformamide (3g). The title compound was prepared according to the general 
procedure A at a temperature of 65 °C for 12 h using cyclopropylamine (35 µL, 0.50 mmol) in a 
                                                          
 
3 T. Nakamura, K. Tateshi, S. Tsukagoshi, S. Hasimoto, S. Watanabe, V. A. Soloshonok, J. L. Acena, O. 




sealed-pressure tube. It was purified by column chromatography using CH2Cl2/EtOAc (80/20 to 
70/30) as the eluent and isolated in the form of a yellow oil (42.2 mg, 0.50 mmol, 99%). 
 
Rf (CH2Cl2/EtOAc: 70/30) = 0.28. The product was obtained in the form of 2 rotamers with a 
ratio of 7:3. 1H NMR (400.0 MHz; CDCl3-d
1) δH = 8.12 (d, J = 11.9 Hz, 0.3HCHO), 8.00 (br s, 
0.7HCHO), 6.97 (br s, 0.7HNH), 6.75 (br s, 0.3HNH), 2.65-2.59 (m, 0.7HCH-NH), 2.58-2.52 (m, 
0.3HCH-NH), 0.71-0.62 (m, 2HCH2), 0.56-0.52 (m, 0.6HCH2), 0.48-0.44 (m, 1.4HCH2). 
13C NMR 
(101.6 MHz; CDCl3-d
1) δC = 166.8 (C=O minor), 162.8 (C=O major), 22.7 (CH minor), 21.2 (CH major), 
6.2 (CH2 minor), 6.0 (CH2 major). ʋmax (neat)/cm
-1 3266, 3016, 2867, 1737, 1651, 1526, 1455, 1385, 
1360, 1262, 1200. HRMS (ESI+ TOF) m/z: [M + Na]+ Calcd for C4H7NONa
+ : 108.0425; Found: 
108.0428. 
 
Morpholine-4-carbaldehyde (3h). Known and described.4 The title compound was prepared 
according to the general procedure A at a temperature of 65 °C for 24 h using morpholine (43 µL, 
0.50 mmol). It was purified by column chromatography using CH2Cl2/EtOAc (80/20 to 70/30) as 
the eluent and isolated in the form of a yellow oil (51.2 mg, 0.44 mmol, 89%). 
 
Rf (CH2Cl2/EtOAc: 70/30) = 0.23. The 
1H and 13C data were consistent with those reported in the 
literature. 1H NMR (400.0 MHz; CDCl3-d
1) δH 8.02 (br s, 1HCHO), 3.67 (t, J = 4.7 Hz, 2HO-CH2-
CH2-N), 3.63 (t, J = 4.6 Hz, 2HO-CH2-CH2-N), 3.54 (t, J = 5.1 Hz, 2HO-CH2-CH2-N), 3.37 (t, J = 5.0 Hz, 
2HO-CH2-CH2-N). 
13C NMR (101.6 MHz; CDCl3-d
1) δC = 160.6 (C=O), 67.0 (CH2), 66.2 (CH2), 45.6 
(CH2), 40.4 (CH2). 
                                                          
 




1-H-Indole-1-carbaldehyde (3i). The title compound was prepared according to the general 
procedure A at a temperature of 65 °C for 24 h using indole (56 µL, 0.50 mmol). It was purified 
by column chromatography using CH2Cl2/EtOAc (90/10) as the eluent and isolated in the form of 
a brown oil (70.6 mg, 0.48 mmol, 96%). 
 
Rf (CH2Cl2/EtOAc: 90/10) = 0.26. The product was obtained in the form of 2 rotamers with a 
ratio of 8:2. 1H NMR (400.0 MHz; CDCl3-d
1) δH = 9.03 (br s, 0.8HCHO), 8.61 (br s, 0.2HCHO), 
7.36-7.25 (m, 3HAr), 7.17-7.13 (m, 1HAr), 4.21 (t, J = 8.4 Hz, 0.5HCH2-CH2-N), 4.16 (td, J = 8.5, 0.9 
Hz, 1.5HCH2-CH2-N), 3.31-3.29 (m, 0.4HCH2-CH2-N), 3.25 (m, 1.6HCH2-CH2-N). 
13C NMR (101.6 MHz; 
CDCl3-d
1) δC = 159.3 (C=O minor), 157.6 (C=O major), 141.0 (CqAr), 131.9 (CqAr), 127.58 (CHAr 
minor), 127.57 (CHAr major), 126.0 (CHAr major), 124.8 (CHAr minor), 124.6 (CHAr minor), 124.3 (CHAr 
major), 116.7 (CHAr minor), 109.4 (CHAr major), 47.0 (CH2 minor), 44.6 (CH2 major), 27.7 (CH2 major), 27.2 
(CH2 minor). ʋmax (neat)/cm
-1 2918, 2851, 1668, 1595, 1494, 1463, 1405, 1363, 1338, 1293, 1267, 
1173. HRMS (ESI+ TOF) m/z: [M + Na]+ Calcd for C9H9NONa
+ : 170.0590; Found: 170.0582. 
 
N-Benzyl-N-methylformamide (3j). Known and described.5 The title compound was prepared 
according to the general procedure A at a temperature of 65 °C for 12 h using N-methyl-1-
phenylmethanamine (65 µL, 0.50 mmol). It was purified by column chromatography using 
pentane/EtOAc (80/20) as the eluent and isolated in the form of a yellow oil (74.4 mg, 0.50 
mmol, 99%).   
 
                                                          
 




Rf (Pentane/EtOAc: 80/20) = 0.13. The product was obtained in the form of 2 rotamers with a 
ratio of 6:4. The 1H and 13C data were consistent with those reported in the literature. 1H NMR 
(400.0 MHz; CDCl3-d
1) δH = 8.21 (br s, 0.6HCHO), 8.08 (br s, 0.4HCHO), 7.32-7.22 (m, 3HAr), 
7.20-7.12 (m, 2HAr), 4.44 (s, 0.8HCH2), 4.31 (s, 1.2HCH2), 2.76 (s, 1.2H, CH3), 2.70 (s, 1.8H, CH3). 
13C NMR (101.6 MHz; CDCl3-d
1) δC = 162.6 (C=O major), 162.4 (C=O minor), 135.8 (CqAr minor), 
135.5 (CqAr major), 128.6 (CHAr major), 128.4 (CHAr minor), 128.0 (CHAr major), 127.8 (CHAr minor), 
127.4 (CHAr minor), 127.2 (CHAr major), 53.2 (CH2 major), 47.5 (CH2 minor), 33.8 (CH3 major), 29.2 (CH3 
minor). 
 
Piperazine-1,4-carbaldehyde (3k). The title compound was prepared according to the general 
procedure A at a temperature of 65 °C for 12 h using piperazine (43.1 mg, 0.50 mmol) under the 
diluted conditions, purified by column chromatography using CH2Cl2/MeOH (90/10) and isolated 
in the form of a yellow oil (68.0 mg, 0.48 mmol, 96%). 
 
Rf (CH2Cl2/MeOH: 90/10) = 0.49. 
1H NMR (400.0 MHz; CDCl3-d
1) δH = 8.03 (br s, 2HCHO), 
3.54-3.52 (m, 2HCH2), 3.47 (s, 2HCH2), 3.37 (s, 2HCH2), 3.34-3.31 (m, 2HCH2). 
13C NMR (101.6 
MHz; CDCl3-d
1) δC = 160.8 (C=O), 160.6 (C=O), 45.8 (CH2), 44.7 (CH2), 40.2 (CH2), 39.2 
(CH2). ʋmax (neat)/cm
-1 3569, 2927, 2871, 2244, 1651, 1432, 1396, 1357, 1277, 1253, 1208, 1182, 
1167. HRMS (ESI+ TOF) m/z: [M + Na]+ Calcd for C6H10N2O2Na
+ : 165.0640; Found: 165.0647. 
 
N-Cyclohexylformamide (3l). Known and described.6 The title compound was prepared 
according to the general procedure A at a temperature of 65 °C for 12 h using cyclohexylamine 
(57 µL, 0.50 mmol) under the diluted conditions. It was purified by column chromatography 
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using CH2Cl2/EtOAc (90/10 to 80/20) as the eluent and isolated in the form of a yellow oil (61.3 
mg, 0.48 mmol, 97%). 
 
Rf (CH2Cl2/EtOAc: 80/20) = 0.26. The product was obtained in the form of 2 rotamers with a 
ratio of 8:2. The 1H and 13C data were consistent with those reported in the literature. 1H NMR 
(400.0 MHz; CDCl3-d
1) δH = 8.06 (br s, 0.2HCHO), 8.02 (br s, 0.8HCHO), 6.24 (br s, 0.2HNH), 6.11 
(br s, 0.8HNH), 3.82-3.73 (m, 0.8HCH), 3.25-3.23 (m, 0.2HCH), 1.89-1.81 (m, 2HCH2), 1.68-1.63 
(m, 2HCH2), 1.57-1.54 (m, 1HCH2), 1.34-1.24 (m, 2HCH2), 1.21-1.08 (m, 3HCH2). 
13C NMR (101.6 
MHz; CDCl3-d
1) δC = 160.5 (C=O), 51.0 (CH), 47.0 (CH2), 34.6 (CH2), 32.9 (CH2), 25.4 (CH2), 
24.7 (CH2). 
 
N-(3,5-bis(Trifluoromethyl)benzyl)formamide (3m). The title compound was prepared 
according to the general procedure A at a temperature of 65 °C for 12 h using 3,5-
bis(trifluoromethyl)-phenylmethanamine (122 mg, 0.50 mmol) under the diluted conditions. It 
was purified by column chromatography using CH2Cl2/EtOAc (70/30) as the eluent and isolated 
in the form of a colorless oil (135.4 mg, 0.50 mmol, 99%). 
 
Rf (CH2Cl2/EtOAc: 70/30) = 0.42. The product was obtained in the form of 2 rotamers with a 
ratio of 9.5:0.5. 1H NMR (400.0 MHz; CDCl3-d
1) δH = 8.25 (br s, 1HCHO), 7.76 (s, 1HAr), 7.72 (s, 
2HAr), 7.09 (br s, 1HNH), 4.54 (d, J = 6.3 Hz, 2HCH2). 
13C NMR (101.6 MHz; CDCl3-d
1) δC = 
164.8 (C=O minor) 161.6 (C=O major) 140.4 (CqAr) 131.9 (q, JC-F = 33.4 Hz, CqCF3) 127.6 (d, JC-F = 
2.6 Hz, CHAr) 123.1 (d, JC-F = 272.8 Hz, CqF) 121.4 (quin, JC-F = 15.2 Hz, CHAr major) 119.0 (CHAr 
minor) 44.8 (CH2 minor) 41.1 (CH2 major). 
19F NMR (375 MHz; CDCl3-d




(neat)/cm-1 3287, 3054, 2877, 1662, 1529, 1381, 1351, 1274, 1167, 1120. HRMS (ESI+ TOF) 
m/z: [M + Na]+ Calcd for C10H7NONa F6
+ :  294.0330; Found: 294.0343. 
 
N-(3-Fluorophenethyl)formamide (3n). The title compound was prepared according to the 
general procedure A at a temperature of 65 °C for 12 h using 2-(3-fluorophenyl)ethan-1-amine 
(65 µL, 0.50 mmol) under the diluted conditions. It was purified by column chromatography 
using CH2Cl2/EtOAc (70/30) as the eluent and isolated in the form of a colorless oil (82.1 mg, 
0.49 mmol, 98%). 
 
Rf (CH2Cl2/EtOAc: 70/30) = 0.25. The product was obtained in the form of 2 rotamers with a 
ratio of 9:1. 1H NMR (400.0 MHz; CDCl3-d
1) δH = 8.05 (br s, 0.9HCHO), 7.82 (d, J = 11.8 Hz, 
0.1HCHO), 7.23 (dd, J = 12.2, 5.5 Hz, 1HAr), 6.94 (d, J = 5.5 Hz, 1HAr), 6.90-6.86 (m, 2HAr), 6.20 
(br s, 1HNH), 3.50 (q, J = 6.8 Hz, 1.7HCH2-CH2-NH), 3.42 (q, J = 6.7 Hz, 0.3HCH2-CH2-NH), 2.79 (t, J = 
7.0 Hz, 2HCH2-CH2-NH). 
13C NMR (101.6 MHz; CDCl3-d
1) δC = 164.5 (C=O minor), 162.8 (d, JC-F = 
246.0 Hz, CqArF), 161.3 (C=O major), 141.0 (d, JC-F = 7.4 Hz, CqAr major), 140.1 (d, JC-F = 7.2 Hz, 
CqAr minor), 130.2 (d, JC-F = 8.3 Hz, CHAr minor), 130.0 (d, JC-F = 8.3 Hz, CHAr major), 124.5 (d, JC-F = 
2.8 Hz, CHAr minor), 124.3 (d, JC-F = 2.8 Hz, CHAr major), 115.6 (d, JC-F = 21.1 Hz, CHAr minor), 
115.48 (d, JC-F = 21.1 Hz, CHAr major), 113.7 (d, JC-F = 20.9 Hz, CHAr minor), 113.4 (d, JC-F = 21.1 
Hz, CHAr major), 42.8 (CH2 minor), 38.9 (CH2 major), 37.2 (d, JC-F = 1.6 Hz, CH2 minor), 35.1 (d, JC-F = 
1.6 Hz, CH2 major). 
19F NMR (375 MHz; CDCl3-d
1) δF = -113.0 (s).  ʋmax (neat)/cm
-1 3281, 3056, 
2936, 2866, 1657, 1616, 1588, 1488, 1449, 1383, 1250, 1140. HRMS (ESI+ TOF) m/z: [M + 
Na]+ Calcd for C9H10NOFNa
+ : 190.0644; Found: 190.0654. 
 
N-Allylformamide (3o). The title compound was prepared according to the general procedure A 




conditions in a sealed-pressure tube. It was purified by column chromatography using 
CH2Cl2/EtOAc (90/10 to 70/30) as the eluent and isolated in the form of a colorless oil (42.6 mg, 
0.50 mmol, 99%). 
 
Rf (CH2Cl2/EtOAc: 90/10) = 0.11. The product was obtained in the form of 2 rotamers with a 
ratio of 9:1. 1H NMR (400.0 MHz; CDCl3-d
1) δH = 8.12 (br s, 0.9HCHO), 7.95 (d, J = 12.0 Hz, 
0.1HCHO), 6.68 (br s, 0.9HNH), 6.38 (br s, 0.1HNH), 5.83-5.70 (m, 1HCH-CH2-NH), 5.20-5.14 (m, 
0.2H(CH)2-C=CH), 5.17-5.07 (m, 1.8H(CH)2-C=CH), 3.83 (t, J = 5.7 Hz, 1.8HCH2-NH), 3.79-3.76 (m, 
0.2HCH2-NH). 
13C NMR (101.6 MHz; CDCl3-d
1) δC = 164.9 (C=O minor), 161.3 (C=O major), 134.2 
(CH minor), 133.4 (CH major), 116.6 (CH minor), 116.3 (CH major), 43.8 (CH2 minor), 40.2 (CH2 major). 
ʋmax (neat)/cm
-1 3284, 3055, 2924, 2867, 1658, 1644, 1532, 1421, 1383, 1338, 1232, 1145. 
HRMS (ESI+ TOF) m/z: [M + Na]+ Calcd for C4H7NONa
+ : 108.0425; Found: 108.0429. 
 
N-Isobutylformamide (3p). Known and described.7 The title compound was prepared according 
to the general procedure B at a temperature of 65 °C for 12 h using isobutylamine (50 µL, 0.50 
mmol) under the diluted conditions in a sealed-pressure tube. It was purified by column 
chromatography using CH2Cl2/EtOAc (80/20) as the eluent and isolated in the form of a colorless 
oil (49.9 mg, 0.49 mmol, 99%). 
 
Rf (CH2Cl2/EtOAc: 80/20) = 0.21. The product was obtained in the form of 2 rotamers with a 
ratio of 9:1. The 1H and 13C data were consistent with those reported in the literature. 1H NMR 
(400.0 MHz; CDCl3-d
1) δH = 8.01 (br s, 0.9HCHO), 7.84 (d, J = 11.9 Hz, 0.1HCHO), 7.05 (br s, 
                                                          
 




1HNH), 2.94 (t, J = 6.5 Hz, 1.6HCH2), 2.87 (t, J = 6.5 Hz, 0.4HCH2), 1.70-1.56 (m, 1HCH), 0.79 (d, J 
= 6.8 Hz, 2 x 3HCH3). 
13C NMR (101.6 MHz; CDCl3-d
1) δC = 165.0 (C=O minor), 161.5 (C=O 
major), 49.1 (CH2 minor), 45.1 (CH2 major), 29.2 (CH minor), 28.0 (CH major), 19.7 (CH3 major), 19.2 (CH3 
minor).  
 
N-Hexylformamide (3q). Known and described.8 The title compound was prepared according to 
the general procedure A at a temperature of 65 °C for 12 h using hexylamine (66 µL, 0.50 mmol) 
under the diluted conditions. It was purified by column chromatography using CH2Cl2/EtOAc 
(70/30) as the eluent and isolated in the form of a yellow oil (63.2 mg, 0.49 mmol, 98%). 
 
Rf (CH2Cl2/EtOAc: 70/30) = 0.42. The product was obtained in the form of 2 rotamers with a 
ratio of 8:2. The 1H and 13C data were consistent with those reported in the literature. 1H NMR 
(400.0 MHz; CDCl3-d
1) δH = 8.16 (br s, 0.8HCHO), 8.04 (d, J = 12.0 Hz, 0.2 HCHO), 5.60 (br s, 
1HNH), 3.30 (q, J = 6.9 Hz, 1.5HCH2-NH), 3.21 (q, J = 6.8 Hz, 0.5HCH2-NH), 1.52 (qiun, J = 7.2 Hz, 
2HCH2-CH2-NH), 1.30 (s, 3 x 2HCH2), 0.89 (t, J = 6.7 Hz, 3HCH3). 
13C NMR (101.6 MHz; CDCl3-d
1) 
δC = 164.8 (C=O minor), 161.3 (C=O major), 41.8 (CH2 minor), 38.1 (CH2 major), 31.3 (CH2 major), 31.2 
(CH2 minor), 31.0 (CH2 minor), 29.3 (CH2 major), 26.4 (CH2 major), 25.9 (CH2 minor), 22.41 (CH2 major), 
22.38 (CH2 minor), 13.9 (CH3 major), 13.8 (CH3 minor).  
6. General Procedure B: N-formylation of α-amino esters using HCONH2 
 
To a sealed tube was added 2-chlorophenylborinic acid 1 (3 mg, 0.0125 mmol, 0.025 equiv.), 
HCONH2 (0.10 mL, 2.5 mmol, 5 equiv.) and acetic acid (3 mg, 0.05 mmol, 3 µL, 0.1 equiv.). The 
mixture was vigorously stirred for 15 min at 45 °C and the α-amino ester amine (0.50 mmol, 1 
equiv.) was then slowly added using a gastight syringe. The resulting mixture was stirred for a 
                                                          
 




further 24 h. The reaction mixture was directly purified using column chromatography using 
CH2Cl2/EtOAc (90/10 to 80/20 and 70/30) as the eluent, unless otherwise stated, to yield the 
corresponding title compounds in good to excellent yields. It should be noted that the density of 
each free amine was determined prior to its addition and the volume was accordingly calculated. 
 
Methyl-N-formyl-glycinate (8a). The title compound was prepared according to the general 
procedure B using glycine methyl ester (40 µL, 0.50 mmol) and isolated in the form of a yellow 
oil (58.2 mg, 0.50 mmol, 99%).  
 
Rf (CH2Cl2/EtOAc: 70/30) = 0.26. 
1H NMR (400.0 MHz; CDCl3-d
1) δH = 8.23 (s, 1HCHO), 6.45 
(br s, 1HNH), 4.08 (d, J = 5.4 Hz, 2HCH2), 3.75 (s, 3HOCH3). 
13C NMR (101.6 MHz; CDCl3-d
1) δC 
= 169.9 (C=Oester), 161.2 (C=O), 52.4 (CH3), 39.7 (CH2). ʋmax (neat)/cm
-1 3316, 3054, 2957, 
2251, 1745, 1662, 1521, 1439, 1385, 1370, 1207, 1183, 1008.  HRMS (ESI+ TOF) m/z: [M + 
Na]+ Calcd for C4H7NO3Na
+ : 140.0324; Found: 140.0327. 
 
(S)-Methyl-N-formyl-alinate (8b). Known and described.9 The title compound was prepared 
according to the general procedure B using of (S)-alanine methyl ester (54 µL, 0.50 mmol) and 
isolated in the form of a brown oil (65.6 mg, 0.50 mmol, 99%, ee: 94%).  
 
[α]D
25 - 53.1° (c 0.6, EtOH), [α]D
25 (lit) - 54.4° (c 0.6, EtOH).10 Rf (CH2Cl2/EtOAc: 70/30) = 0.21. 
The 1H and 13C data were consistent with those reported in the literature. 1H NMR (400.0 MHz; 
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1) δH = 8.14 (br s, 1HCHO), 6.63 (br s, 1HNH), 4.63 (q, J = 7.2 Hz, 1HCH), 3.72 (s, 
3HOCH3), 1.40 (d, J = 7.2 Hz, 3HCH3). 
13C NMR (101.6 MHz; CDCl3-d
1) δC = 172.9 (C=O), 160.5 
(C=O), 52.4 (CH3), 46.6 (CH), 18.2 (CH3).  
 
(S)-Methyl-N-formyl-phenylalinate (8c). Known and described.11 The title compound was 
prepared according to the general procedure B using of (S)-phenylalanine methyl ester (82 µL, 
0.50 mmol) and isolated in the form of a colorless oil (101.9 mg, 0.49 mmol, 98%, ee: 92%).  
 
[α]D
25 + 82.3° (c 2.0, EtOH), [α]D
25 (lit) + 86.1° (c 2.0, EtOH).12 Rf (CH2Cl2/EtOAc: 70/30) = 
0.38. The 1H and 13C data were consistent with those reported in the literature. 1H NMR (400.0 
MHz; CDCl3-d
1) δH = 8.11 (br s, 1HCHO), 7.30-7.22 (m, 3HAr), 7.11-7.09 (m, 2HAr), 6.39 (d, J = 
6.3 Hz, 1HNH), 4.94 (q, J = 7.6 Hz, 1HCH-CH2), 3.72 (s, 3HOCH3), 3.15 (dd, J = 13.9, 6.6 Hz, 1HCH-
CH2), 3.09 (dd, J = 13.9, 5.6 Hz, 1HCH-CH2). 
13C NMR (101.6 MHz; CDCl3-d
1) δC = 171.5 
(C=Oester), 160.6 (C=O), 135.4 (CqAr), 129.1, (CHAr), 128.5 (CHAr), 127.1 (CHAr), 52.3 (CH3), 
51.7 (CH), 37.5 (CH2).  
 
(S)-Methyl-N-formyl-leucinate (8d). The title compound was prepared according to the general 
procedure B using of (S)-leucine methyl ester (72 µL, 0.50 mmol) and isolated in the form of a 
yellow oil (83.9 mg, 0.484 mmol, 97%).  
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25 + 4.2° (c 1.0, CHCl3), [α]D
25 (lit) + 4.1° (c 1.0, CHCl3).
13 Rf (CH2Cl2/EtOAc: 90/10) = 0.26. 
1H NMR (400.0 MHz; CDCl3-d
1) δH = 8.18 (br s, 1HCHO), 6.46 (br s, 1HNH), 4.69 (td, J = 8.8, 4.5 
Hz, 1HCH2-CH-NH), 3.71 (s, 3HOCH3), 1.66-1.58 (m, 2HCH2-CH-NH), 1.56-1.51 (m, 1H(CH3)2CH), 0.92 
(m, 2 x 3HCH3). 
13C NMR (101.6 MHz; CDCl3-d
1) δC = 173.1 (C=Oester), 160.8 (C=O), 52.3 
(CH3), 49.2 (CH), 41.4 (CH2), 24.7 (CH), 22.6 (CH3), 21.7 (CH3). ʋmax (neat)/cm
-1 2924, 2957, 
1744, 1661, 1531, 1437, 1384, 1076. HRMS (ESI+ TOF) m/z: [M + Na]+ Calcd for C8H15NO3Na
+ 
: 196.0950; Found: 196.0954. 
 
(S)-Methyl-N-formyl-valinate (8e). The title compound was prepared according to the general 
procedure B using of (S)-valine methyl ester (70 µL, 0.50 mmol) and isolated in the form of a 
yellow oil (76.7 mg, 0.48 mmol, 96%, ee> 99%).  
 
[α]D
25 + 22.2° (c 1.0, CHCl3), [α]D
25 (lit) + 28.2° (c 1.0, CHCl3).
14 Rf (CH2Cl2/EtOAc: 70/30) = 
0.33. 1H NMR (400.0 MHz; CDCl3-d
1) δH = 8.21 (br s, 1HCHO), 6.64 (d, J = 5.5 Hz, 1HNH), 4.60 
(dd, J = 9.0, 4.9 Hz, 1HCH2-CH-NH), 3.70 (s, 3HOCH3), 2.19-2.11- (m, 1H(CH3)2CH), 0.92 (d, J = 6.8 
Hz, 3HCH3), 0.87 (d, J = 6.8 Hz, 3HCH3). 
13C NMR (101.6 MHz; CDCl3-d
1) δC = 172.1 (C=Oester), 
161.1 (C=O), 55.5 (CH), 52.1 (CH3), 31.0 (CH), 18.8 (CH3), 17.5 (CH3). ʋmax (neat)/cm
-1 3303, 
2968, 2877, 2251, 1739, 1662, 1520, 1466, 1437, 1384, 1372, 1268, 1182, 1138. HRMS (ESI+ 
TOF) m/z: [M + Na]+ Calcd for C7H14NO3Na
+ : 182.0793; Found: 182.0803. 
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(S)-Methyl-N-formylmethioninate (8f). Known and described.9 The title compound was 
prepared according to the general procedure B using of (S)-methionine methyl ester (75 µL, 0.50 
mmol) and isolated in the form of a yellow oil (87.1 mg, 0.456 mmol, 91%, ee: 90%). 
 
[α]D
25 + 39.4° (c 1.0, CHCl3), [α]D
25 (lit) + 38.8° (c 1.0, CHCl3).
9 Rf (CH2Cl2/EtOAc: 70/30) = 
0.54. The 1H and 13C data were consistent with those reported in the literature. 1H NMR (400.0 
MHz; CDCl3-d
1) δH = 8.17 (s, 1HCHO), 6.85 (d, J = 6.4 Hz, 1HNH), 4.76-4.71 (m, 1HCH2-CH-NH), 
3.71 (s, 3HOCH3), 2.47 (t, J = 7.5 Hz, 2HSMe-CH2-CH2-CH), 2.17-2.08 (m, 1HSMe-CH2-CH2-CH), 2.04 (s, 
3HSCH3), 2.0-1.93 (m, 1HCH2-CH2-CH). 
13C NMR (101.6 MHz; CDCl3-d
1) δC = 172.0 (C=Oester), 
161.0 (C=O), 52.5 (CH3), 49.9 (CH), 31.3 (CH2), 29.7 (CH2), 15.2 (CH3). 
 
(S)-Methyl-N-formylprolinate (8g). Known and described.9 The title compound was prepared 
according to the general procedure B using of (S)-proline methyl ester (60 µL, 0.50 mmol) and 
isolated in the form of a yellow oil (78.2 mg, 0.50 mmol, 99%).  
 
[α]D
25 – 109.7° (c 1.0, CHCl3), [α]D
25 (lit) -89.5° (c 1.0, CHCl3).
9 Rf (CH2Cl2/EtOAc: 70/30) = 
0.32. The product was obtained in the form of 2 rotamers with a ratio of 6:4. The 1H and 13C data 
were consistent with those reported in the literature. 1H NMR (400.0 MHz; CDCl3-d
1) δH = 8.22 
(br s, 0.6HCHO), 8.18 (br s, 0.4HCHO), 4.40-4.38 (m, 1HCH) 3.70 (s, 1.2HOCH3), 3.67 (s, 1.8HOCH3) 
3.63-3.53 (m, 1HCH2-N), 3.48-3.45 (m, 1HCH2-N), 2.24-2.13 (m, 2HCH2-CH2-CH), 2.00-1.85 (m, 2HCH2-
CH2-CH). 
13C NMR (101.6 MHz; CDCl3-d
1) δC = 172.0 (C=Oester minor), 171.9 (C=Oester major), 161.4 
(C=O minor), 160.6 (s, C=O major), 58.4 (CH major), 56.2 (CH minor), 52.5 (CH3 minor), 52.1 (CH3 major), 





(S)-Methyl-N6-Boc-N-formyllysinate (8h). Known and described.9 The title compound was 
prepared according to the general procedure B using of (S)-lysine methyl ester (130.2 mg, 0.50 
mmol) and isolated in the form of a yellow oil (143.8 mg, 0.50 mmol, 99%).  
 
[α]D
25 + 10.2° (c 1.0, CHCl3), [α]D
25 (lit) + 12.6° (c 1.0, CHCl3).
9 Rf (CH2Cl2/EtOAc: 70/30) = 
0.20. The 1H and 13C data were consistent with those reported in the literature. 1H NMR (400.0 
MHz; CDCl3-d
1) δH = 8.18 (br s, 1HCHO), 6.70 (d, J = 6.1 Hz, 1HNH), 4.72 (t, J = 5.3 Hz, 1HBoc-
NH), 4.63-4.58 (m, 1HCH2-CH-NH), 3.72 (s, 3HOCH3), 3.08-3.06 (m, 2HBocNH-CH2-CH2), 1.90-1.82 (m, 
1HCH2-CH2-CH-NH), 1.75-1.65 (m, 1HCH2-CH2-CH-NH), 1.52-1.44 (m, 2HBocNH- CH2-CH2-CH2), 1.40 (s, 
9H(CH3)3C=O), 1.36-1.30 (m, 2HBocNH-CH2-CH2-CH2). 
13C NMR (101.6 MHz; CDCl3-d
1) δC =172.4 
(C=Oester), 160.9 (C=O), 156.2 (C=OBoc), 79.1 (Cq), 52.4 (CH3), 50.6 (CH), 39.6 (CH2), 31.4 
(CH2), 29.4 (CH2), 28.3 (CH3), 22.1 (CH2).  
 
(S)-Dimethyl-N-formylglutamate (8i). The title compound was prepared according to the 
general procedure B using of (S)-glutamate dimethyl ester (87.6 µL, 0.50 mmol) and isolated in 
the form of a yellow oil (58.2 mg, 0.29 mmol, 57%).  
 
[α]D
25 + 66.9° (c 1.4, CHCl3), [α]D
25 (lit) + 69.7° (c 1.4, CHCl3).
15 Rf (CH2Cl2/EtOAc: 70/30) = 
0.24. 1H NMR (400.0 MHz; CDCl3-d
1) δH = 8.21 (br s, 1HCHO), 6.55 (d, J = 4.6 Hz, 1HNH), 4.73-
4.68 (m, 1HCH-NH), 3.75 (s, 3HOCH3), 3.66 (s, 3HOCH3), 2.48-2.35 (m, 2HCH2-CH2-CH-NH), 2.27-2.19 
(m, 1HCH2-CH2-CH-NH), 2.06-1.97 (m, 1HCH2-CH2-CH-NH). 
13C NMR (101.6 MHz; CDCl3-d
1) δC = 
173.1 (C=Oester), 171.9 (C=O ester next to (CH)), 160.8 (C=O), 52.6 (CH3), 51.8 (CH3), 50.2 (CH), 29.8 
                                                          
 





(CH2), 27.2 (CH2). ʋmax (neat)/cm
-1 3322, 2956, 2927, 2857, 2254, 1733, 1668, 1525, 1437, 1384, 
1335, 1260, 1204, 1172. HRMS (ESI+ TOF) m/z:  [M + Na]+ Calcd for C8H13NO5Na
+ : 226.0691; 
Found: 226.0699. 
(S,S)-Dimethyl-5,10-dioxo-1,6-diazecane-2,7-dicarboxylate (9). The title compound was 
prepared according to the general procedure A at a temperature of 65 °C for 48 h using of (S)-
glutamate dimethyl ester (87.6 µL, 0.50 mmol) under the diluted conditions, purified by column 
chromatography using CH2Cl2/EtOAc (80/20) and isolated in the form of a yellow oil (65.1 mg, 
0.23 mmol, 91%). 
 
[α]D
25 + 0.69 ° (c 1.0, CHCl3), (no reported [α]D
25 in lit). Rf (CH2Cl2/EtOAc: 80/20) = 0.26. 
1H 
NMR (400.0 MHz; CDCl3-d
1) δH = 6.82 (br s, 2HNH), 4.27-4.24 (m, 2 x 1HCH-NH), 3.76 (s, 2 x 
3HCH3), 2.51-2.41 (m, 2HCH2-CH2-CH-NH), 2.39-2.28 (m, 2 x 2HCH2-CH2-CH-NH), 2.25-2.18 (m, 2HCH2-
CH2-CH-NH). 
13C NMR (101.6 MHz; CDCl3-d
1) δC =178.2 (C=O), 172.6 (C=O), 55.4 (CH), 52.6 
(CH3), 29.2 (CH2), 24.8 (CH2). ʋmax (neat)/cm
-1 3231, 2956, 1739, 1694, 1437, 1378, 1205, 1152, 
1113, 1042, 1023. HRMS (ESI+ TOF) m/z: [M + Na]+ Calcd for C12H18N2O6Na
+ : 309.1064; 
Found: 309.1076. 
7. Procedure C: One-Pot Synthesis of an Isocyanide from Benzylamine 
 
To a round-bottom flask under an argon atmosphere were added 2-chlorophenylborinic acid 1 
(12.5 mg, 0.05 mmol, 0.1 equiv.), dry DMF (7 mL) and acetic acid (6 mg, 0.10 mmol, 6 µL, 0.2 
equiv.) at 65 °C. The mixture was vigorously stirred for 15 mins and the amine (0.50 mmol, 1 
equiv.) was then slowly added using a gastight 100 μL syringe. The resulting mixture was stirred 
for 12 h at 65 °C. After 12 h, Burgess reagent (360 mg, 1.5 mmol, 3 equiv.), trimethylamine (418 
µL, 3 mmol, 6 equiv.) and 5 Å powdered molecular sieves (1 g) were added and stirring was 
maintained for further 48 h. The reaction mixture was extracted five times with Et2O and H2O in 




vacuum. The crude mixture was purified by column chromatography using Pentane/EtOAc as the 
eluent to give the desired isocyanides. 
Benzyl isocyanide (10). Known and described.16 The title compound was prepared according to 
the procedure C using benzylamine (55 µL, 0.50 mmol). It was purified by column 
chromatography using Pentane /EtOAc (80/20 to 50/50) as the eluent to yield the title compound 
as an orange oil (43.9 mg, 0.33 mmol, 65%). 
 
Rf (CH2Cl2/EtOAc: 95/5) = 0.55. The 
1H and 13C data were consistent with those reported in the 
literature. 1H NMR (400.0 MHz; CDCl3-d
1) δH = 7.43-7.34 (m, 5HAr), 4.55 (s, 2HCH2). 
13C NMR 
(101.6 MHz; CDCl3-d
1) δC = 157.7 (t, J = 5.4 Hz, CN), 132.3 (CqAr), 129.0 (CHAr), 128.4 (CHAr), 
126.6 (CHAr), 45.5 (t, J = 7.3 Hz, CH2).  
                                                          
 




8. 1H and 13C NMR Spectra of the Synthesised products 
 
1H NMR (400.0 MHz; CDCl3) of 3a. 
 





1H NMR (400.0 MHz; CDCl3) of 3b. 
 





1H NMR (400.0 MHz; CDCl3) of 3c. 
 





1H NMR (400.0 MHz; MeOH-d4) of 3d. 
 





1H NMR (400.0 MHz; CDCl3) of 3e. 
 





1H NMR (400.0 MHz; CDCl3) of 3f. 
 





1H NMR (400.0 MHz; CDCl3) of 3g.  
 





1H NMR (400.0 MHz; CDCl3) of 3h. 
 





1H NMR (400.0 MHz; CDCl3) of 3i. 
 





1H NMR (400.0 MHz; CDCl3) of 3j. 
 





1H NMR (400.0 MHz; CDCl3) of 3k. 
 





1H NMR (400.0 MHz; CDCl3) of 3l. 
 





1H NMR (400.0 MHz; CDCl3) of 3m. 
 





1H NMR (400.0 MHz; CDCl3) of 3n. 
 




1H NMR (400.0 MHz; CDCl3) of 3o. 
 





1H NMR (400.0 MHz; CDCl3) of 3p. 
 





1H NMR (400.0 MHz; CDCl3) of 3q. 
 





1H NMR (400.0 MHz; CDCl3) of 8a. 
 





1H NMR (400.0 MHz; CDCl3) of 8b. 
 





1H NMR (400.0 MHz; CDCl3) of 8c. 
 





1H NMR (400.0 MHz; CDCl3) of 8d. 
 





1H NMR (400.0 MHz; CDCl3) of 8e. 
 





1H NMR (400.0 MHz; CDCl3) of 8f.  
 





1H NMR (400.0 MHz; CDCl3) of 8g. 
 





1H NMR (400.0 MHz; CDCl3) of 8h. 
 





1H NMR (400.0 MHz; CDCl3) of 8i. 
 





1H NMR (400.0 MHz; CDCl3) of 9 
 





1H NMR (400.0 MHz; CDCl3) of 10 
 











































(S)- Methyl-N-formylmethioninate 8f (Procedure B, HCONH2 at 45 °C) 
 
